Global and Regional Estimates for Subtype-Specific Therapeutic and Prophylactic HIV-1 Vaccines: A Modeling Study

Archive ouverte

Elangovan, Ramyiadarsini | Jenks, Michael | Yun, Jason | Dickson-Tetteh, Leslie | Kirtley, Shona | Hemelaar, Joris | Abimiku, Alash'Le | Agwale, Simon | Archibald, Chris | Avidor, Boaz | Barbás, María Gabriela | Barré-Sinoussi, Françoise | Barugahare, Banson | Belabbes, El Hadj | Bertagnolio, Silvia | Birx, Deborah | Bobkov, Aleksei | Brandful, James | Bredell, Helba | Brennan, Catherine | Brooks, James | Bruckova, Marie | Buonaguro, Luigi | Buonaguro, Franco | Buttò, Stefano | Buvé, Anne | Campbell, Mary | Carr, Jean | Carrera, Alex | Carrillo, Manuel Gómez | Celum, Connie | Chaplin, Beth | Charles, Macarthur | Foulongne, Vincent | Vande Perre, Philippe | Reynes, Jean-Marc

Edité par CCSD ; Frontiers Media -

International audience. Global HIV-1 genetic diversity forms a major obstacle to the development of an HIV vaccine. It may be necessary to employ subtype-specific HIV-1 vaccines in individual countries according to their HIV-1 subtype distribution. We estimated the global and regional need for subtype-specific HIV-1 vaccines. We took into account the proportions of different HIV-1 variants circulating in each country, the genetic composition of HIV-1 recombinants, and the different genome segments ( gag , pol , env ) that may be incorporated into vaccines. We modeled different scenarios according to whether countries would employ subtype-specific HIV-1 vaccines against (1) the most common subtype; (2) subtypes contributing more than 5% of HIV infections; or (3) all circulating subtypes. For therapeutic vaccines targeting the most common HIV-1 subtype in each country, 16.5 million doses of subtype C vaccine were estimated globally, followed by subtypes A (14.3 million) and B (4.2 million). A vaccine based on env required 2.6 million subtype E doses, and a vaccine based on pol required 4.8 million subtype G doses. For prophylactic vaccines targeting the most common HIV-1 subtype in each country, 1.9 billion doses of subtype A vaccine were estimated globally, followed by subtype C (1.1 billion) and subtype B (1.0 billion). A vaccine based on env required 1.2 billion subtype E doses, and a vaccine based on pol required 0.3 billion subtype G doses. If subtype-specific HIV-1 vaccines are also directed against less common subtypes in each country, vaccines targeting subtypes D, F, H, and K are also needed and would require up to five times more vaccine doses in total. We conclude that to provide global coverage, subtype-specific HIV-1 vaccines need to be directed against subtypes A, B, and C. Vaccines targeting env also need to include subtype E and those targeting pol need to include subtype G.

Suggestions

Du même auteur

Global and regional epidemiology of HIV-1 recombinants in 1990–2015: a systematic review and global survey

Archive ouverte | Hemelaar, Joris | CCSD

International audience. Background: Global HIV-1 genetic diversity and evolution form a major challenge to treatment and prevention efforts. An increasing number of distinct HIV-1 recombinants have been identified w...

Global and regional molecular epidemiology of HIV-1, 1990–2015: a systematic review, global survey, and trend analysis

Archive ouverte | Hemelaar, Joris | CCSD

International audience. Global genetic diversity of HIV-1 is a major challenge to the development of HIV vaccines. We aimed to estimate the regional and global distribution of HIV-1 subtypes and recombinants during ...

Global and regional molecular epidemiology of HIV-1, 1990–2015: a systematic review, global survey, and trend analysis

Archive ouverte | Hemelaar, Joris | CCSD

Erratum in: Correction to Lancet Infect Dis 2019; 19: 143-55. [Lancet Infect Dis. 2020]. International audience. Global genetic diversity of HIV-1 is a major challenge to the development of HIV vaccines. We aimed t...

Chargement des enrichissements...